Our findings indicate that Pioglitazone mitigates chondrocyte inflammation and osteoarthritis in murine models by inhibiting the expression of inflammatory mediators such as TNF‐α, IL‐6 and PGE2, and by preventing the degradation of aggrecan and collagen II. Here, TNF is linked to osteoarthritis.